Immune-Onc Therapeutics, Inc., a Palo Alto, CA-based biopharmaceutical company focused on advancing promising immuno-oncology therapeutics, raised $7m in Series A financing.
Backers included Fame Mount Limited and CLI Ventures.
The company intends to use the funds for the discovery and development of its novel antibodies.
Co-founded in 2016 by Charlene Liao, Ph.D., who serves as its President and CEO, and Guo-Liang Yu, Ph.D., a serial entrepreneur and industry veteran, Immune-Onc Therapeutics focuses on developing innovative therapeutic antibodies for cancer treatment. The company is applying scientific insights and expertise in drug development to advance novel immuno-oncology products and bring new treatment options to cancer patients.